Obiettivo The department of Oncology of Crucell Holland BV, lead by Renate Zwijsen (PhD) is actively involved in the development and the commercialisation of monoclonal human antibodies, applying its MAbstract target discovery and antibody development technology and its PER.C6 human cell line technology for high-yielding antibody production.The department of Oncology intends on initiating a breast cancer research program aimed specifically at identifying antigens that are uniquely expressed in breast cancer and, thereafter, at developing human antibodies that selectively bind to these identified antigens. For this project, Crucell Holland BV has an exclusive arrangement with the University Medical Centre of Utrecht (UMC Utrecht) through which Crucell Holland BV will have a constant supply of fresh breast cancer tissue samples to be used for this research project. Campo scientifico medical and health sciencesclinical medicineoncologybreast cancer Programma(i) FP5-HUMAN POTENTIAL - Programme for research, technological development and demonstration on "Improving the human research potential and the socio-economic knowledge base" (1998-2002) Argomento(i) Data not available Invito a presentare proposte IHP-MCHI-01-1 Vedi altri progetti per questo bando Meccanismo di finanziamento Data not available Coordinatore CRUCELL HOLLAND B.V. Contributo UE Nessun dato Indirizzo Archimedesweg 4 LEIDEN Paesi Bassi Mostra sulla mappa Costo totale Nessun dato
